[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carbapenem-resistant-bacterial-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carbapenem-resistant-bacterial-infection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,71,101],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100510106","phase-4-cefiderocol-and-ampicillin-sulbactam-vs-colistin---meropenem-for-carbapenem-resistant-a-baumannii-100510106",false,"NCT05922124","Cefiderocol and Ampicillin-sulbactam vs. Colistin +\u002F- Meropenem for Carbapenem Resistant A. Baumannii","Cefiderocol and Ampicillin-sulbactam vs. Colistin or Colistin-meropenem for Carbapenem Resistant Acinetobacter Baumannii Bacteremia or Hospital-acquired Pneumonia: Controlled Clinical Study With Historical Controls (CASCADE)","CASCADE","Inclusion Criteria:\n\nAdults \\>18 years with bacteremia or hospital-acquired pneumonia (HAP)\u002F ventilator-associated pneumonia (VAP) (Table 3) caused by carbapenem-resistant A. baumannii (CRAB) (meropenem and\u002F or imipenem minimal inhibitory concentration (MIC) \\>8 μg\u002FmL) susceptible to cefiderocol (disc zone diameter \\>=17 mm, corresponding to an MIC \\\u003C2 μg\u002FmL). We will include CRAB regardless of colistin, ampicillin-sulbactam, minocycline, tigecycline, trimethoprim\u002Fsulfamethoxazole and\u002For aminoglycoside susceptibility of the isolate. Attribution of the HAP\u002F VAP to CRAB will be allowed with isolation of CRAB from any respiratory sample within 7 days prior to the clinical diagnosis of pneumonia.\n\nExclusion Criteria:\n\n* More than 72 hours of therapy with in-vitro coverage against the CRAB within 96 hours of enrolment\n* Polymicrobial carbapenem-susceptible infections: growth of other pathogens susceptible to carbapenems, or another beta-lactam, deemed clinically-significant by the treating physicians in blood or sputum (with HAP\u002F VAP). We will allow recruitment of patients with other carbapenem-resistant Gram-negative bacteria\n* CRAB susceptible any beta-lactam other than cefiderocol\n* Coronavirus 2019 (COVID-19) co-infection\n* Immediate-type hypersensitivity to penicillin\n* Pregnant women\n* Previous participation in the trial\n* Lack of informed consent, considering the procedures acceptable to ethics committees per locale, including deferred consent\n* Infection requiring treatment for over 14 days, at the discretion of the investigators\n* Life expectancy less than 24 hours or expected futility of antibiotic treatment","ALL","16 Years",{"count":20,"type":21},734,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Patients with bloodstream infections, hospital acquired pneumonia or ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB) treated with cefiderocol combined with ampicillin sulbactam will be compared to patients treated treated with colistin alone or colistin combined with meropenem.",[27,28,29],"Carbapenem Resistant Bacterial Infection","Acinetobacter Bacteremia","Acinetobacter Pneumonia","RECRUITING","2025-07-29",{"date":33,"type":34},"2025-08-01","ACTUAL",{"date":36,"type":34},"2024-09-01",{"date":38,"type":21},"2026-09",{"name":40,"class":41},"Rambam Health Care Campus","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100593254","phase-4-optimising-treatment-for-severe-gram-negative-bacterial-infections-100593254","NCT07004049","Optimising TREATment for Severe Gram-Negative Bacterial Infections","TREAT-GNB [CR-GNB]","TREAT-GNB","Inclusion Criteria:\n\nA: Bloodstream infections\n\na) Suitable for at least 2 antibiotic regimens in the site randomisation list\n\n1. Growth of Gram-negative bacilli identified from blood culture(s)\n2. Receiving or planning to receive intravenous antibiotics\n3. Expected time from blood culture sampling to randomisation is ≤ 96 hours.\n\nOR\n\nB: Ventilator-associated pneumonia \u002F hospital-acquired pneumonia a) Suitable for at least 2 antibiotic regimens in the site randomisation list b) Infection syndrome definitions\\^( (US Centers for Disease Control and Prevention National Healthcare Safety Network)3: i) At least one of the following:\n\n1. temperature \\> 38 °C\n2. white blood cell count ≥ 12,000 cells\u002Fmm3 (12 x 109\u002FL, 12 x 103\u002FµL) or ≤ 4,000 cells\u002Fmm3 (4 x 109\u002FL, 4 x 103\u002FµL)\n3. altered mental status with no other causes in \\> 70 years old; AND ii) Two or more chest imaging tests demonstrating at least one of the following:\n\n1\\) new and progressive OR progressive and persistent infiltrate 2) new and persistent OR progressive and persistent consolidation 3) new and persistent OR progressive and persistent cavitation; AND iii) At least two of the following:\n\n1. new onset of purulent sputum, or change in character of sputum, or increased respiratory secretions, or increased in suctioning requirements\n2. new onset or worsening tachypnoea or dyspnoea\n3. rales or bronchial breath sounds\n4. worsening gas exchange defined by oxygen desaturations (e.g., PaO2\u002FFiO2 \\\u003C 240), increased oxygen requirements or increased ventilation demand.\n\n   c) Hospital admission \\> 48 hours d) Predominant growth of Gram-negative bacilli identified from respiratory tract specimen(s)\\*; e) Receiving or planning to receive intravenous antibiotics f) Expected time from respiratory culture sampling to randomisation is ≤ 96 hours\n\n   AND\n\n   C: CR-GNB antibiotic backbone domain\n\n   a) Gram-negative bacilli belonging to Acinetobacter baumannii-calcoaceticus complex, Pseudomonas aeruginosa or Enterobacterales b) Carbapenem resistance in isolate detected - i) Phenotypically via conventional microbiology testing: meropenem \u002F imipenem \u002F ertapenem resistance; OR ii) Genotypically via PCR or next generation sequencing: presence of genes associated with carbapenemase production (eg. blaNDM, blaKPC, blaIMP, blaIMI, blaVIM, blaOXA-48-like).\n\n   Exclusion Criteria:\n   1. Treating team deems enrolment in the study is not in the best interest of the patient\n   2. Patient is on end-of-life care\n   3. Patient is incarcerated in a correctional facility\n   4. Participation in any interventional study activities outlined in the TREAT-GNB study within the last 90 days\n   5. Pregnant women and children\n\n      OR\n   6. Polymicrobial bloodstream infection","18 Years",{"count":53,"type":21},600,[24],"TREAT-GNB is an innovative trial to expedite the evaluation of various antibiotic choices and treatment strategies for severe multidrug-resistant Gram-negative bacterial infections, specifically bloodstream and lower respiratory tract infections. This approach combines platform trial elements with adaptive clinical designs to streamline the evaluation of various treatment options and optimise resource utilisation. The overall aim of the TREAT-GNB platform trial is to identify interventions that improve survival in patients with severe infections due to Gram-negative bacteria.\n\nIn the CR-GNB silo of TREAT-GNB, the primary objective is to quantify the effect on all-cause mortality at 28 days of a range of interventions in patients with bloodstream infections, ventilator-associated pneumonia, and hospital-acquired pneumonia caused by CR-GNB.",[57,58,59,27,60],"Bloodstream Infection","Ventilator Associated Bacterial Pneumonia","Hospital Acquired Bacterial Pneumonia","Multidrug Resistance","2025-05-26",{"date":63,"type":34},"2025-06-04",{"date":65,"type":34},"2025-04-21",{"date":67,"type":21},"2028-12-31",{"name":69,"class":41},"National University of Singapore",41,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":78,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100535955","dynamics-of-colonization-and-infection-by-multidrug-resistant-pathogens-in-immunocompromised-and-critically-ill-patients-100535955","NCT06258551","Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients","DYNAMITE","Inclusion Criteria:\n\n* Admission to an intensive care unit or stem cell transplant unit (for allogeneic stem cell transplantation) within previous 24 hours\n\nExclusion Criteria:\n\n* \\\u003C18 years of age\n* Pregnancy\n* History of inflammatory bowel disease (Crohn's disease, ulcerative colitis)\n* Gastrointestinal derivation (colostomy, ileostomy, etc.)",true,{"count":80,"type":21},1000,"OBSERVATIONAL","The goal of this observational study is to investigate how bacterial populations from the intestine and mouth of patients change during the hospitalization period and evaluate if some populations of specific bacteria increase or decrease the risk of acquiring an infection or becoming colonized by pathogenic bacteria. Participants will have the following samples collected during enrollment: stool samples (maximum 2x\u002Fweek), blood draws (1x\u002Fweek), oral swab (1x\u002Fweek).",[84,85,86,87,88,89,27,90],"Antimicrobial Drug Resistance","Antibiotic Resistant Infection","Clostridium Difficile","Carbapenem-Resistant Enterobacteriaceae Infection","Extended Spectrum Beta-Lactamase Producing Bacteria Infection","Vancomycin Resistant Enterococci Infection","Vancomycin-Resistant Enterococcal Infection","2024-02-06",{"date":93,"type":34},"2024-02-14",{"date":95,"type":34},"2020-12-08",{"date":97,"type":21},"2026-06",{"name":99,"class":41},"The Methodist Hospital Research Institute",2,{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":51,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100515182","efficacy-and-safety-of-carrimycin-tablets-in-hlh-patients-with-carbapenem-resistant-infections-100515182","NCT05988177","Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections","Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* Active infection；\n* Empirical treatment with carbapenems did not respond after 72 hours；\n* Age \\>18 years old, no gender limitation;\n* Ability and willingness to adhere to the study visit schedule and all protocol requirements.\n\nExclusion Criteria:\n\n* Other antibiotics should be selected according to the results of drug sensitivity；\n* Systemic antibiotics other than carbapenems are used with 72 hours；\n* Inability to take oral medications due to disease of gastrointestinal tract；\n* Severe liver insufficiency;\n* Expected survival time \\\u003C 1 month;\n* Pregnant or breasting-feeding women;\n* Allergic to Carrimycin tablets;\n* Active hepatitis B or hepatitis C infection;\n* Patients with HIV infection;\n* Patients with other contraindications considered unsuitable for participation in this study.",{"count":109,"type":21},20,[111],"NA","This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.",[27,114],"Hemophagocytic Lymphohistiocytoses","NOT_YET_RECRUITING","2023-08-04",{"date":118,"type":34},"2023-08-14",{"date":120,"type":21},"2023-08-30",{"date":122,"type":21},"2026-12-30",{"name":124,"class":41},"Beijing Friendship Hospital",1]